

Oguz Akin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3373155/publications.pdf>

Version: 2024-02-01

131
papers

6,724
citations

53794

45
h-index

64796

79
g-index

139
all docs

139
docs citations

139
times ranked

6555
citing authors

#	ARTICLE	IF	CITATIONS
1	Heat Modulation of Intrinsic MR Contrasts for Tumor Characterization. <i>Cancers</i> , 2022, 14, 405.	3.7	0
2	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	1.9	22
3	In Vivo Renal Lipid Quantification by Accelerated Magnetic Resonance Spectroscopic Imaging at 3T: Feasibility and Reliability Study. <i>Metabolites</i> , 2022, 12, 386.	2.9	3
4	Evaluation of cancer outcome assessment using MRI: A review of deep-learning methods. <i>BJR Open</i> , 2022, 4, .	0.6	0
5	LGAN: Lung segmentation in CT scans using generative adversarial network. <i>Computerized Medical Imaging and Graphics</i> , 2021, 87, 101817.	5.8	41
6	A dual-modal PET/near infrared fluorescent nanotag for long-term immune cell tracking. <i>Biomaterials</i> , 2021, 269, 120630.	11.4	27
7	Diffusion-weighted MRI and histogram analysis: assessment of response to neoadjuvant chemotherapy in nephroblastoma. <i>Abdominal Radiology</i> , 2021, 46, 3317-3325.	2.1	2
8	Simultaneous injection of 18F-BF3- Cy3-ACUPA and non-radioactive Cy7-ACUPA probes: a promising pre-biopsy PET and ex vivo fluorescence imaging approach to evaluate prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3732-3733.	6.4	4
9	Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 259-281.	3.8	29
10	Uncontrolled Confounders May Lead to False or Overvalued Radiomics Signature: A Proof of Concept Using Survival Analysis in a Multicenter Cohort of Kidney Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 638185.	2.8	10
11	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 791.e17-791.e24.	1.6	3
12	The Anatomical Relationships in the Space of Retzius for Penile Implants: An MRI Analysis. <i>Journal of Sexual Medicine</i> , 2021, 18, 1830-1834.	0.6	1
13	Small Molecule, Multimodal, [18F]-PET and Fluorescence Imaging Agent Targeting Prostate-Specific Membrane Antigen: First-in-Human Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 405-416.	1.9	13
14	Preoperative nomogram predicting 12-year probability of metastatic renal cancer – evaluation in a contemporary cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 853.e1-853.e7.	1.6	6
15	Climacturia After Radical Prostatectomy: MRI-Based Predictors. <i>Journal of Sexual Medicine</i> , 2020, 17, 1723-1728.	0.6	2
16	Accelerating Prostate Diffusion-weighted MRI Using a Guided Denoising Convolutional Neural Network: Retrospective Feasibility Study. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e200007.	5.8	23
17	Renal cell carcinoma: Associations between tumor imaging features and epidemiological risk factors. <i>European Journal of Radiology</i> , 2020, 129, 109096.	2.6	5
18	Diffusion-weighted MRI in the assessment of nephroblastoma: results of a multi-center trial. <i>Abdominal Radiology</i> , 2020, 45, 3202-3212.	2.1	22

#	ARTICLE	IF	CITATIONS
19	An evaluation of the role of tumor load in cytoreductive nephrectomy. Canadian Urological Association Journal, 2020, 14, E625-E630.	0.6	1
20	Diffusion-Weighted Imaging. , 2020, , 65-74.		0
21	A near-infrared probe for non-invasively monitoring cerebrospinal fluid flow by 18F-positron emitting tomography and fluorescence. EJNMMI Research, 2020, 10, 37.	2.5	4
22	Temporal changes in MRI appearance of the prostate after focal ablation. Abdominal Radiology, 2019, 44, 272-278.	2.1	12
23	The Influence of Background Signal Intensity Changes on Cancer Detection in Prostate MRI. American Journal of Roentgenology, 2019, 212, 823-829.	2.2	16
24	A Fluorescent, [¹⁸ F]-Positron-Emitting Agent for Imaging Prostate-Specific Membrane Antigen Allows Genetic Reporting in Adoptively Transferred, Genetically Modified Cells. ACS Chemical Biology, 2019, 14, 1449-1459.	3.4	14
25	Three novel methods to measure the postoperative displacement of lower urinary tract structures following radical prostatectomy in a sample of Korean patients. BMC Urology, 2019, 19, 54.	1.4	4
26	Nonenhancing Component of Clear Cell Renal Cell Carcinoma on Computed Tomography Correlates With Tumor Necrosis and Stage and Serves as a Size-Independent Prognostic Biomarker. Journal of Computer Assisted Tomography, 2019, 43, 628-633.	0.9	5
27	Characterization of prostate cancer with MR spectroscopic imaging and diffusion-weighted imaging at 3-Tesla. Magnetic Resonance Imaging, 2019, 55, 93-102.	1.8	17
28	Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. Journal of Urology, 2018, 200, 275-282.	0.4	31
29	¹⁸ F-Positron Emitting/Trimethine Cyanine-Fluorescent Contrast for Image-Guided Prostate Cancer Management. Journal of Medicinal Chemistry, 2018, 61, 4256-4262.	6.4	40
30	Influence of Contrast Administration on Computed Tomography-Based Analysis of Visceral Adipose and Skeletal Muscle Tissue in Clear Cell Renal Cell Carcinoma. Journal of Parenteral and Enteral Nutrition, 2018, 42, 1148-1155.	2.6	36
31	Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia. Leukemia Research, 2018, 68, 48-50.	0.8	2
32	Model selection for high b-value diffusion-weighted MRI of the prostate. Magnetic Resonance Imaging, 2018, 46, 21-27.	1.8	7
33	ACR Appropriateness Criteria® Pretreatment Staging of Muscle-Invasive Bladder Cancer. Journal of the American College of Radiology, 2018, 15, S150-S159.	1.8	36
34	Effect of intravascular contrast agent on diffusion and perfusion fraction coefficients in the peripheral zone and prostate cancer. Magnetic Resonance Imaging, 2018, 51, 120-127.	1.8	1
35	The measurement of membranous urethral length using transperineal ultrasound prior to radical prostatectomy. Scandinavian Journal of Urology, 2018, 52, 263-268.	1.0	7
36	An in-vivo pilot study into the effects of FDG-mNP in cancer in mice. PLoS ONE, 2018, 13, e0202482.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Preoperative Prostate MRI: A Road Map for Surgery. American Journal of Roentgenology, 2018, 211, 383-391.	2.2	26
38	Preoperative Membranous Urethral Length Measurement and Continence Recovery Following Radical Prostatectomy: A Systematic Review and Meta-analysis. European Urology, 2017, 71, 368-378.	1.9	164
39	Differentiation of Clear Cell Renal Cell Carcinoma From Other Renal Cortical Tumors by Use of a Quantitative Multiparametric MRI Approach. American Journal of Roentgenology, 2017, 208, W85-W91.	2.2	40
40	Benign and tumor parenchyma metabolomic profiles affect compensatory renal growth in renal cell carcinoma surgical patients. PLoS ONE, 2017, 12, e0180350.	2.5	2
41	Dynamic contrast-enhanced magnetic resonance imaging of prostate cancer: A review of current methods and applications. World Journal of Radiology, 2017, 9, 416-425.	1.1	36
42	Irreversible Electroporation for Prostate Cancer as Salvage Treatment Following Prior Radiation and Cryotherapy. Reviews in Urology, 2017, 19, 268-272.	0.9	3
43	Improved noninvasive prostate cancer assessment using multiparametric magnetic resonance imaging. , 2016, , .		1
44	Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. Clinical Genitourinary Cancer, 2016, 14, 56-62.	1.9	7
45	Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival. American Journal of Roentgenology, 2016, 206, 1023-1030.	2.2	33
46	Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours. European Journal of Cancer, 2016, 59, 57-64.	2.8	15
47	Assessment of Prostate Cancer Aggressiveness by Use of the Combination of Quantitative DWI and Dynamic Contrast-Enhanced MRI. American Journal of Roentgenology, 2016, 206, 756-763.	2.2	56
48	Use of DWI in the Differentiation of Renal Cortical Tumors. American Journal of Roentgenology, 2016, 206, 100-105.	2.2	61
49	An Arterial Based Complexity (ABC) Scoring System to Assess the Morbidity Profile of Partial Nephrectomy. European Urology, 2016, 69, 72-79.	1.9	75
50	Preoperative predictive model of recovery of urinary continence after radical prostatectomy. BJU International, 2015, 116, 577-583.	2.5	88
51	Volume and landmark analysis: comparison of MRI measurements obtained with an endorectal coil and with a phased-array coil. Clinical Radiology, 2015, 70, 379-386.	1.1	1
52	Interactive Feature Space Explorer® for multi-modal magnetic resonance imaging. Magnetic Resonance Imaging, 2015, 33, 804-815.	1.8	2
53	Comparison of Prostate Volume Measured by Endorectal Coil MRI to Prostate Specimen Volume and Mass After Radical Prostatectomy. Academic Radiology, 2015, 22, 556-562.	2.5	20
54	Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas®“Renal Cell Carcinoma (TCGA®“RCC) Imaging Research Group. Abdominal Imaging, 2015, 40, 1684-1692.	2.0	84

#	ARTICLE	IF	CITATIONS
55	Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI. European Radiology, 2015, 25, 2665-2672.	4.5	57
56	Interobserver variability of R.E.N.A.L., PADUA, and centrality index nephrometry score systems. World Journal of Urology, 2015, 33, 853-858.	2.2	47
57	Subcentimeter Pulmonary Nodules are Not Associated with Disease Progression in Patients with Renal Cell Carcinoma. Journal of Urology, 2015, 193, 776-782.	0.4	18
58	Anatomic segmentation improves prostate cancer detection with artificial neural networks analysis of ¹ H magnetic resonance spectroscopic imaging. Journal of Magnetic Resonance Imaging, 2014, 40, 1414-1421.	3.4	24
59	Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations. Radiology, 2014, 270, 464-471.	7.3	226
60	Prostate Cancer Aggressiveness: Assessment with Whole-Lesion Histogram Analysis of the Apparent Diffusion Coefficient. Radiology, 2014, 271, 143-152.	7.3	255
61	Prostate MRI: Evaluating Tumor Volume and Apparent Diffusion Coefficient as Surrogate Biomarkers for Predicting Tumor Gleason Score. Clinical Cancer Research, 2014, 20, 3705-3711.	7.0	69
62	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. Clinical Cancer Research, 2014, 20, 1955-1964.	7.0	208
63	MR imaging of renal cortical tumours: qualitative and quantitative chemical shift imaging parameters. European Radiology, 2013, 23, 1738-1744.	4.5	81
64	Peritoneal inclusion cysts: clinical characteristics and imaging features. European Radiology, 2013, 23, 1167-1174.	4.5	35
65	Image Artifacts on Prostate Diffusion-weighted Magnetic Resonance Imaging. Academic Radiology, 2013, 20, 1041-1047.	2.5	59
66	MRI findings of radiation-induced changes in the urethra and periurethral tissues after treatment for prostate cancer. European Journal of Radiology, 2013, 82, e775-e781.	2.6	19
67	Diffusion-weighted MRI of the prostate at 3.0T: Comparison of endorectal coil (ERC) MRI and phased-array coil (PAC) MRI – The impact of SNR on ADC measurement. European Journal of Radiology, 2013, 82, e515-e520.	2.6	33
68	Re: Prospective Evaluation of MRI, 11 C-Acetate PET/CT and Contrast-Enhanced CT for Staging of Bladder Cancer. Journal of Urology, 2013, 190, 1713-1714.	0.4	0
69	CT of Renal Cell Carcinoma: Assessment of Collecting System Invasion. American Journal of Roentgenology, 2013, 201, W821-W827.	2.2	14
70	Role of CT in the Assessment of Muscular Venous Branch Invasion in Patients With Renal Cell Carcinoma. American Journal of Roentgenology, 2013, 201, 847-852.	2.2	8
71	Transition Zone Prostate Cancer: Incremental Value of Diffusion-weighted Endorectal MR Imaging in Tumor Detection and Assessment of Aggressiveness. Radiology, 2013, 269, 493-503.	7.3	100
72	Renal Cell Carcinoma: Role of MR Imaging in the Assessment of Muscular Venous Branch Invasion. Radiology, 2013, 267, 454-459.	7.3	18

#	ARTICLE	IF	CITATIONS
73	Multiparametric Prostate MR Imaging with T2-weighted, Diffusion-weighted, and Dynamic Contrast-enhanced Sequences: Are All Pulse Sequences Necessary to Detect Locally Recurrent Prostate Cancer after Radiation Therapy?. Radiology, 2013, 268, 440-450.	7.3	109
74	Stage IB1 Cervical Cancer: Role of Preoperative MR Imaging in Selection of Patients for Fertility-Sparing Radical Trachelectomy. Radiology, 2013, 269, 149-158.	7.3	72
75	Multiphasic contrast-enhanced MRI: Single-slice versus volumetric quantification of tumor enhancement for the assessment of renal clear-cell carcinoma fuhrman grade. Journal of Magnetic Resonance Imaging, 2013, 37, 1160-1167.	3.4	35
76	Early Postoperative CT as a Prognostic Biomarker in Patients With Advanced Ovarian, Tubal, and Primary Peritoneal Cancer Deemed Optimally Debulked at Primary Cytoreductive Surgery. American Journal of Roentgenology, 2012, 198, 1453-1459.	2.2	21
77	MR Imaging of Treated Prostate Cancer. Radiology, 2012, 262, 26-42.	7.3	120
78	Value of the Hemorrhage Exclusion Sign on T1-weighted Prostate MR Images for the Detection of Prostate Cancer. Radiology, 2012, 263, 751-757.	7.3	80
79	Normal Central Zone of the Prostate and Central Zone Involvement by Prostate Cancer: Clinical and MR Imaging Implications. Radiology, 2012, 262, 894-902.	7.3	104
80	Performance Characteristics of MR Imaging in the Evaluation of Clinically Low-Risk Prostate Cancer: A Prospective Study. Radiology, 2012, 265, 478-487.	7.3	81
81	Pretreatment Endorectal Coil Magnetic Resonance Imaging Findings Predict Biochemical Tumor Control in Prostate Cancer Patients Treated With Combination Brachytherapy and External-Beam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, 707-711.	0.8	34
82	Recovery of Urinary Function After Radical Prostatectomy: Predictors of Urinary Function on Preoperative Prostate Magnetic Resonance Imaging. Journal of Urology, 2012, 187, 945-950.	0.4	89
83	Motion Correction of Multi-b-value Diffusion-weighted Imaging in the Liver. Academic Radiology, 2012, 19, 1573-1580.	2.5	33
84	The Incremental Value of Contrast-Enhanced MRI in the Detection of Biopsy-Proven Local Recurrence of Prostate Cancer After Radical Prostatectomy: Effect of Reader Experience. American Journal of Roentgenology, 2012, 199, 360-366.	2.2	51
85	Advances in oncologic imaging. Ca-A Cancer Journal for Clinicians, 2012, 62, 364-393.	329.8	53
86	Prospective evaluation of MRI, 11C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. European Journal of Radiology, 2012, 81, 4131-4137.	2.6	66
87	Magnetic Resonance Imaging for Predicting Prostate Biopsy Findings in Patients Considered for Active Surveillance of Clinically Low Risk Prostate Cancer. Journal of Urology, 2012, 188, 1732-1738.	0.4	201
88	Renal Cortical Tumors: Use of Multiphasic Contrast-enhanced MR Imaging to Differentiate Benign and Malignant Histologic Subtypes. Radiology, 2012, 264, 779-788.	7.3	86
89	Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer. BJU International, 2012, 109, 1315-1322.	2.5	93
90	Reducing the influence of b-value selection on diffusion-weighted imaging of the prostate: Evaluation of a revised monoexponential model within a clinical setting. Journal of Magnetic Resonance Imaging, 2012, 35, 660-668.	3.4	32

#	ARTICLE	IF	CITATIONS
91	Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU International, 2012, 109, 1636-1647.	2.5	103
92	Do pelvic dimensions and prostate location contribute to the risk of experiencing complications after radical prostatectomy?. BJU International, 2011, 108, 1566-1571.	2.5	9
93	Pelvimetric Dimensions do not Impact upon Nerve Sparing or Erectile Function Recovery in Patients Undergoing Radical Retropubic Prostatectomy. Journal of Sexual Medicine, 2011, 8, 567-574.	0.6	5
94	Primary seminal vesicle adenocarcinoma. Clinical Imaging, 2011, 35, 480-482.	1.5	13
95	Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. European Radiology, 2011, 21, 1970-1978.	4.5	79
96	Bland and tumor thrombi in abdominal malignancies: magnetic resonance imaging assessment in a large oncologic patient population. Abdominal Imaging, 2011, 36, 62-68.	2.0	48
97	The Value of MR Imaging When the Site of Uterine Cancer Origin Is Uncertain. Radiology, 2011, 258, 785-792.	7.3	39
98	Diffusion-weighted Endorectal MR Imaging at 3 T for Prostate Cancer: Tumor Detection and Assessment of Aggressiveness. Radiology, 2011, 259, 775-784.	7.3	377
99	Imaging assessment of tumor response: past, present and future. Future Oncology, 2011, 7, 669-677.	2.4	14
100	Interactive dedicated training curriculum improves accuracy in the interpretation of MR imaging of prostate cancer. European Radiology, 2010, 20, 995-1002.	4.5	85
101	Semi-automatic deformable registration of prostate MR images to pathological slices. Journal of Magnetic Resonance Imaging, 2010, 32, 1149-1157.	3.4	40
102	The depth of the prostatic apex is an independent predictor of positive apical margins at radical prostatectomy. BJU International, 2010, 106, 622-626.	2.5	30
103	Are histopathological features of prostate cancer lesions associated with identification of extracapsular extension on magnetic resonance imaging?. BJU International, 2010, 106, 1303-1308.	2.5	14
104	Clinical Value of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography in Bladder Cancer. Journal of Clinical Oncology, 2010, 28, 3973-3978.	1.6	165
105	Focal Treatment or Observation of Prostate Cancer: Pretreatment Accuracy of Transrectal Ultrasound Biopsy and T2-weighted MRI. Urology, 2010, 75, 472-477.	1.0	38
106	Residual Prostate Tissue After Radical Prostatectomy: Acceptable Surgical Complication or Treatment Failure?. Urology, 2010, 76, 1136-1137.	1.0	3
107	Ethnic Variation in Pelvimetric Measures and Its Impact on Positive Surgical Margins at Radical Prostatectomy. Urology, 2010, 76, 1092-1096.	1.0	29
108	Multimodality Magnetic Resonance Imaging of Prostate Cancer. Journal of Endourology, 2010, 24, 677-684.	2.1	29

#	ARTICLE	IF	CITATIONS
109	Pure Primary Prostatic Osteosarcoma Arising in a Non-Irradiated Prostate. Urologia Internationalis, 2009, 83, 236-238.	1.3	4
110	Prostate Tumor Volume Measurement with Combined T2-weighted Imaging and Diffusion-weighted MR: Correlation with Pathologic Tumor Volume. Radiology, 2009, 252, 449-457.	7.3	194
111	Clinical Stage T1c Prostate Cancer: Evaluation with Endorectal MR Imaging and MR Spectroscopic Imaging. Radiology, 2009, 253, 425-434.	7.3	57
112	Recovery of Urinary Continence after Radical Prostatectomy: Association with Urethral Length and Urethral Fibrosis Measured by Preoperative and Postoperative Endorectal Magnetic Resonance Imaging. European Urology, 2009, 55, 629-639.	1.9	186
113	Local changes in bone marrow at MRI after treatment of extremity soft tissue sarcoma. Skeletal Radiology, 2009, 38, 11-19.	2.0	29
114	The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer. Clinical Advances in Hematology and Oncology, 2009, 7, 193-202.	0.3	21
115	Perihepatic Metastases from Ovarian Cancer: Sensitivity and Specificity of CT for the Detection of Metastases with and Those without Liver Parenchymal Invasion. Radiology, 2008, 248, 511-517.	7.3	46
116	Detection of Prostate Cancer with MR Spectroscopic Imaging: An Expanded Paradigm Incorporating Polyamines. Radiology, 2007, 245, 499-506.	7.3	88
117	Endorectal MRI of Prostatic and Periprostatic Cystic Lesions and Their Mimics. American Journal of Roentgenology, 2007, 188, 1373-1379.	2.2	50
118	Imaging of Prostate Cancer. Radiologic Clinics of North America, 2007, 45, 207-222.	1.8	89
119	Ovarian Cancer. Radiologic Clinics of North America, 2007, 45, 149-166.	1.8	53
120	Imaging of Uterine Cancer. Radiologic Clinics of North America, 2007, 45, 167-182.	1.8	58
121	Value of Whole-Body Turbo Short Tau Inversion Recovery Magnetic Resonance Imaging With Panoramic Table For Detecting Bone Metastases. Journal of Computer Assisted Tomography, 2006, 30, 151-156.	0.9	26
122	Evaluation of focal liver lesions: fast-recovery fast spin echo T2-weighted MR imaging. Clinical Imaging, 2006, 30, 322-325.	1.5	5
123	Endorectal MR Imaging in the Evaluation of Seminal Vesicle Invasion: Diagnostic Accuracy and Multivariate Feature Analysis. Radiology, 2006, 238, 929-937.	7.3	140
124	Endorectal MR Imaging before Salvage Prostatectomy: Tumor Localization and Staging. Radiology, 2006, 238, 176-183.	7.3	138
125	Transition Zone Prostate Cancers: Features, Detection, Localization, and Staging at Endorectal MR Imaging. Radiology, 2006, 239, 784-792.	7.3	369
126	Preoperative local staging of rectal cancer with endorectal MR imaging. Clinical Imaging, 2004, 28, 432-438.	1.5	18

#	ARTICLE	IF	CITATIONS
127	The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer, 2004, 100, 2655-2663.	4.1	181
128	Contrast-enhanced magnetic resonance angiography: evaluation of renal arteries in living renal transplant donors. European Journal of Radiology, 2004, 52, 84-93.	2.6	7
129	Local staging of prostate cancer with endorectal surface coil MR imaging in a mid-field magnetic system. Clinical Imaging, 2003, 27, 47-51.	1.5	8
130	Biliary Adenofibroma with Malignant Transformation and Pulmonary Metastases: CT Findings. American Journal of Roentgenology, 2002, 179, 280-281.	2.2	41
131	Magnetic resonance imaging of prostate cancer. , 0, , 140-157.		0